Metropolitan Life Insurance CO Cerevel Therapeutics Holdings, Inc. Transaction History

Metropolitan Life Insurance CO

$253 Million
Q2 2024

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$40.88 - $43.27 $6,377 - $6,750	-156 Reduced 3.91%	3,833 $162,000
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $7,439 - $15,575	367 Added 10.13%	3,989 $169,000
Q3 2023 Nov 14, 2023	BUY	$20.26 - $31.91 $4,538 - $7,147	224 Added 6.59%	3,622 $79,000
Q2 2023 Aug 10, 2023	BUY	$23.9 - $35.38 $2,461 - $3,644	103 Added 3.13%	3,398 $108,000
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $6,663 - $10,313	-292 Reduced 8.14%	3,295 $80,000
Q4 2022 Jun 14, 2023	BUY	$25.35 - $31.96 $7,402 - $9,332	292 Added 8.86%	3,587 $113 Million
Q4 2022 Mar 30, 2023	BUY	$25.35 - $31.96 $6,084 - $7,670	240 Added 7.17%	3,587 $113,000
Q4 2022 Feb 15, 2023	BUY	$25.35 - $31.96 $6,084 - $7,670	240 Added 7.17%	3,587 $113,000
Q3 2022 Jun 14, 2023	BUY	$25.5 - $41.42 $1,326 - $2,153	52 Added 1.58%	3,347 $94.6 Million
Q2 2022 Jun 20, 2023	BUY	$20.62 - $37.15 $1,072 - $1,931	52 Added 1.58%	3,347 $88,000
Q2 2022 Mar 30, 2023	BUY	$20.62 - $37.15 $11,217 - $20,209	544 Added 19.41%	3,347 $88,000
Q2 2022 Aug 11, 2022	BUY	$20.62 - $37.15 $11,217 - $20,209	544 Added 19.41%	3,347 $88,000
Q1 2022 Jun 20, 2023	SELL	$23.5 - $35.38 $11,562 - $17,406	-492 Reduced 14.93%	2,803 $98,000
Q1 2022 Mar 30, 2023	SELL	$23.5 - $35.38 $218,197 - $328,503	-9,285 Reduced 76.81%	2,803 $98,000
Q1 2022 May 12, 2022	SELL	$23.5 - $35.38 $218,197 - $328,503	-9,285 Reduced 76.81%	2,803 $98,000
Q4 2021 Jun 21, 2023	BUY	$29.21 - $44.64 $256,843 - $392,519	8,793 Added 266.86%	12,088 $391,000
Q4 2021 Mar 30, 2023	BUY	$29.21 - $44.64 $10,369 - $15,847	355 Added 3.03%	12,088 $391,000
Q4 2021 Feb 15, 2022	BUY	$29.21 - $44.64 $10,369 - $15,847	355 Added 3.03%	12,088 $392,000
Q3 2021 Jun 21, 2023	BUY	$21.26 - $38.85 $179,391 - $327,816	8,438 Added 256.08%	11,733 $346,000
Q3 2021 Mar 30, 2023	SELL	$21.26 - $38.85 $8,929 - $16,317	-420 Reduced 3.46%	11,733 $346,000
Q3 2021 Nov 15, 2021	SELL	$21.26 - $38.85 $8,929 - $16,317	-420 Reduced 3.46%	11,733 $346,000
Q2 2021 Jun 21, 2023	BUY	$12.56 - $29.69 $111,256 - $262,994	8,858 Added 268.83%	12,153 $311,000
Q2 2021 Mar 30, 2023	BUY	$12.56 - $29.69 $107,588 - $254,324	8,566 Added 238.81%	12,153 $311,000
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $152,641 - $360,822	12,153 New	12,153 $311,000

Others Institutions Holding CERE

# of Institutions

242

Shares Held

154M

Call Options Held

2.19M

Put Options Held

3.87M

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Account